Skip to main content
. 2021 Apr 15;11(2):87–98.

Table 1.

Demographic characteristics at time of initial diagnosis

Positive study (n=7) Negative study (n=21) Overall (n=28)
Age, years
    Median (range) 61.1 (50.8-71.2) 59.5 (54-76.1) 60.6 (50.8-76.1)
PSA at diagnosis, ng/mL
    Median (range) 5.6 (1.4-40.0) 7.1 (3.4-24.6) 6.6 (1.4-40.0)
Gleason score, n (%)
    6-7 2 (28.6) 11 (52.4) 13 (46.4)
    8-10 5 (71.4) 10 (47.6) 15 (53.6)
T classification, n (%)
    T1-T2 2 (28.6) 8 (38.1) 10 (35.7)
    T3-T4 5 (71.4) 9 (42.9) 14 (50)
    Tx 0 4 (19) 4 (14.3)
N classification, n (%)
    N0 5 (71.4) 12 (57.1) 17 (60.7)
    N1 1 (14.3) 3 (14.3) 4 (14.3)
    Nx 1 (14.3) 6 (28.6) 7 (25)
M classification, n (%)
    M0 6 (85.7) 18 (85.7) 24 (85.7)
    M1 0 1 (4.8) 1 (3.6)
    Mx 1 (14.3) 2 (9.5) 3 (10.7)
Extra-prostatic extension, n (%)
    Absence 1 (14.3) 5 (23.8) 6 (21.4)
    Presence 4 (57.1) 9 (42.9) 13 (46.4)
    Unknown 2 (28.6) 7 (33.3) 9 (32.1)
Surgical margin, n (%)
    Negative 4 (57.1) 7 (33.3) 11 (39.3)
    Positive 2 (28.6) 7 (33.3) 9 (32.1)
    Unknown 1 (14.3) 7 (33.3) 8 (28.6)
Seminal vesicle invasion, n (%)
    Absence 2 (28.6) 7 (33.3) 9 (32.1)
    Presence 3 (42.9) 7 (33.3) 10 (35.7)
    Unknown 2 (28.6) 7 (33.3) 9 (32.1)
Lymphovascular invasion, n (%)
    Absence 2 (28.6) 2 (9.5) 4 (14.3)
    Presence 2 (28.6) 6 (28.6) 8 (28.6)
    Unknown 3 (42.9) 13 (61.9) 16 (57.1)
Perineural invasion, n (%)
    Absence 0 0 0
    Presence 4 (57.1) 8 (38.1) 12 (42.9)
    Unknown 3 (42.9) 13 (61.9) 16 (57.1)
Risk classification, n (%)
    Intermediate 1 (14.3) 4 (19) 5 (17.9)
    High 3 (42.9) 4 (19) 7 (25)
    Very high 3 (42.9) 8 (38.1) 11 (39.3)
    Unknown 0 5 (23.8) 5 (17.9)

PSA, prostate-specific antigen.